Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2003

View Archived Issues

Targeted Genetics and Cystic Fibrosis Foundation Therapeutics collaborate on tgAAV-CF

NIH offers licenses to new chondropsin V-ATPase inhibitor

Effective back and leg pain alleviation reported with infliximab in sciatica

Donepezil plus conventional neuroleptics effective for psychotic symptoms in AD

Tadalafil confirmed to be effective and well tolerated in patients with erectile dysfunction

A potential new indication described for mycophenolate mofetil

Greater benefits found for sildenafil plus sertraline in premature ejaculation

Antitumor efficacy reported for a novel monoclonal antibody in advanced renal cell carcinoma

Highly potent Pfs inhibitors identified at Quorex as potential broad-spectrum antimicrobials

Testosterone gel restores physiological serum levels of testosterone in hypogonadal men

BMS researchers design novel chemokine CCR3 receptor modulators

SCI-induced bladder hyperreflexia improved by NK2 receptor antagonists

New cathepsin inhibitors with utility in osteoporosis therapy reported by Celera

New CXCR2 antagonists and their use in rheumatoid arthritis and COPD

Zeria researchers present new H+/K+-ATPase inhibitors

Novel 5-HT receptor modulators in early development at Pharmacia

Macrocyclic antibacterial agents prepared and tested at Bayer

Indole-based prostanoid DP receptor antagonists newly discovered at Ono

Merck scientists isolate a novel HIV integrase inhibitor from Cytospora cultures

Another series of alpha2/alpha3-selective GABA-A modulators reported by Merck

Celgene discusses progress during the first quarter

First-quarter highlights at Tularik

Nippon Boehringer Ingelheim and Sankyo intend to comarket Alesion

MedImmune postpones MEDI-507 trials in psoriasis

GenVec and NIAID to develop SARS vaccine

Search for SARS treatment at Medarex and MBL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...